Similar articles

• Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.

  DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, Foulkes A, Gimotty P, Glick J, Weber B, Stadtmauer E, Rebbeck TR. DeMichele A, et al. J Clin Oncol. 2005 Aug 20;23(24):5552-9. doi: 10.1200/JCO.2005.06.208. J Clin Oncol. 2005. Retraction in: J Clin Oncol. 2006 Jul 10;24(20):3315. doi: 10.1200/JCO.2006.06.001. PMID: 16110016 Retracted.
• In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort".

  DeMichele A, Gimotty P, Botbyl J, Aplenc R, Colligon T, Foulkes AS, Rebbeck TR. DeMichele A, et al. J Clin Oncol. 2007 Dec 10;25(35):5675-7. doi: 10.1200/JCO.2006.10.1485. J Clin Oncol. 2007. PMID: 18065748 No abstract available.
• Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.

  Agarwal G, Tulsyan S, Lal P, Mittal B. Agarwal G, et al. World J Surg. 2016 Jul;40(7):1600-10. doi: 10.1007/s00268-015-3263-6. World J Surg. 2016. PMID: 26506825
• Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.

  Bosch TM. Bosch TM. Methods Mol Biol. 2008;448:63-76. doi: 10.1007/978-1-59745-205-2_5. Methods Mol Biol. 2008. PMID: 18370231 Review.
• Pharmacogenomics and breast cancer.

  Lymberis SC, Parhar PK, Katsoulakis E, Formenti SC. Lymberis SC, et al. Pharmacogenomics. 2004 Jan;5(1):31-55. doi: 10.1517/phgs.5.1.31.25686. Pharmacogenomics. 2004. PMID: 14683419 Review.